血管紧张素转化酶2受体及ACEI或ARB类药物与新型冠状病毒肺炎的相关性  

Correlation Between COVID-19 and ACE2 Receptor and ACEI or ARB Drugs

作　　者：翟利杰 王乔羽 赵志刚[1] ZHAI Lijie;WANG Qiaoyu;ZHAO Zhigang(Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100070

出　　处：《医药导报》2020年第5期633-636,共4页Herald of Medicine

摘　　要：患有高血压的新型冠状病毒肺炎(COVID-19)患者是否可以使用血管紧张素转化酶抑制剂(ACEI)或血管紧张素2受体拮抗剂(ARB)类药物引起关注。该文对COVID-19与血管紧张素转化酶2(ACE2),以及ACEI或ARB类药物与ACE2的相关性进行探讨,结合目前已知证据提出ACEI或ARB类药物与COVID-19可能的相关性。建议目前已使用ACEI或ARB类药物高血压患者不需停药,而未使用者应谨慎选用。As for the use of angiotensin converting enzyme inhibitors(ACEI)or angiotensinⅡreceptor blocker(ARB)drugs in hypertension patients with coronavirus disease 2019(COVID-19),this paper have studied the relationship between COVID-19 and angiotensin converting enzyme 2(ACE2)and the relationship between ACE2 and ACEI or ARB drugs.The possible relationship between ACEI or ARB drugs and COVID-19 was proposed based on the known evidence.The results suggest that patients with hypertension who have used ACEI or ARB drugs do not need to stop taking the drugs,while for those who have never used those antihypertensive drugs,ACEI or ARB drugs is administered must be careful.

关 键 词：新型冠状病毒肺炎 新型冠状病毒 血管紧张素转化酶2 血管紧张素转化酶抑制剂 血管紧张素2受体拮抗剂 

分 类 号：R972.4[医药卫生—药品] R544.1[医药卫生—药学]